Symyx Launches Contract Development and Manufacturing Organization for Biopharmaceuticals
News Apr 23, 2009
Symyx Technologies, Inc. has announced the launch of the Symyx Contract Development and Manufacturing Organization (CDMO). The Symyx CDMO helps biopharmaceutical companies move promising drug candidates to clinical trials faster and reliably with integrated formulation development, and preclinical and CGMP fill/finish manufacturing.
"After discovery, the next critical milestone in drug development is getting to clinical trials quickly with a reliable formulation. The Symyx CDMO provides clients a faster, more reliable route to clinical trials," said Richard Boehner, president of Symyx High Productivity Research (HPR). “We do this by combining unsurpassed formulation expertise, high-productivity research technology and CGMP clinical manufacturing in a single facility."
With expertise in preformulation development, formulation optimization and stability, and analytical method development, the Symyx CDMO enables development of highly optimized and robust drug formulations, so that clinical trials test the efficacy of drug candidates, not the limitations of the formulation.
In addition, the Symyx CDMO offers full service fill/finish execution for delivering drug products manufactured under CGMP conditions while maintaining the integrity of drug substances and meeting preclinical and Phase I and II clinical trial schedules.
Algorithm Speeds Up Medical Image Analysis 1000 TimesNews
Medical image registration is a common technique that involves overlaying two images, such as magnetic resonance imaging (MRI) scans, to compare and analyze anatomical differences in great detail. Researchers have described a machine-learning algorithm that can register brain scans and other 3-D images more than 1,000 times more quickly using novel learning techniques.
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.
Towards Personalized Medicine: One Type of Data is Not EnoughNews
To understand the biology of diseased organs researchers use different types of molecular data. One of the biggest computational challenges at the moment is integrating these multiple data types. A new computational method jointly analyses different types of molecular data and disentangles the sources of disease variability to guide personalized treatment.READ MORE